智翔金泰连跌4天，工银瑞信基金旗下1只基金位列前十大股东

Company Overview - Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. was established in 2015 and is located in Chongqing International Biological City, focusing on antibody drug discovery technology for autoimmune diseases, infectious diseases, and tumors [1] - The company engages in the research, production, and commercialization of antibody drugs [1] Financial Performance - Zhixiang Jintai has experienced a cumulative decline of -6.90% over four consecutive trading days as of May 12 [1] - The fund under ICBC Credit Suisse, ICBC Frontier Medical Stock A, has reduced its holdings in Zhixiang Jintai during the first quarter of this year [1] - The fund has achieved a year-to-date return of 5.63%, ranking 363 out of 999 in its category [1] Fund Manager Profile - Zhao Bei is the fund manager of ICBC Frontier Medical Stock A, with a master's degree and previous experience as an investment manager assistant at Zhongzai Asset Management Co., Ltd. [3][4] - Zhao has been with ICBC Credit Suisse since 2010 and has held various managerial positions, including leading the healthcare research team [3][4] - Zhao has managed multiple funds, including the ICBC Healthcare Industry Stock Fund and the ICBC Pension Industry Stock Fund, with a total management experience of over 10 years [4]